Brief: Lantheus Receives Complete Response Letter From FDA For Lnth-2501 (Ga 68 Edotreotide)
26/06/2026 23:33
BRIEF-Lantheus Receives Complete Response Letter From FDA For Lnth-2501 (Ga 68 Edotreotide) June 26 (Reuters) - Lantheus Holdings Inc LNTH.O:
LANTHEUS RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR LNTH-2501 (GA 68 EDOTREOTIDE)
LANTHEUS HOLDINGS - FDA CANNOT APPROVE LNTH-2501 NDA BY JUNE 29, 2026 DUE TO MANUFACTURING CONDITIONS
LANTHEUS HOLDINGS - LNTH-2501 NDA APPROVAL REQUIRES RESOLUTION OF FACILITY INSPECTION CONDITIONS
LANTHEUS HOLDINGS - CRL DOES NOT IDENTIFY DATA, SAFETY, OR EFFICACY CONCERNS FOR LNTH-2501
Source text: ID:nGNX19FQfC
Further company coverage: LNTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantheus Holdings
See all newsBrief: Lantheus Receives Complete Response Letter From FDA For Lnth-2501 (Ga 68 Edotreotide)
US FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issues (updated)
US FDA declines to approve Lantheus’ tumor imaging kit
$7 billion could be a 'light' price tag for Lantheus, Truist analysts say
Lantheus falls after report it is considering potential $7 billion sale